GAD Autoantibody Affinity in Adult Patients With Latent Autoimmune Diabetes, the Study Participants of a GAD65 Vaccination Trial
- Stephanie Krause1,
- Ulrike Landherr2,
- Carl-David Agardh3,†,
- Simone Hausmann1,
- Katarina Link3,
- Jesse M. Hansen2,
- Kristian F. Lynch4,
- Michael Powell5,
- Jadwiga Furmaniak5,
- Bernard Rees-Smith5,
- Ezio Bonifacio6,
- Anette G. Ziegler1,2,
- Åke Lernmark3 and
- Peter Achenbach1,2⇑
- 1Institute of Diabetes Research, Helmholtz Zentrum München, and Forschergruppe Diabetes, Klinikum rechts der Isar, Technische Universität München, Neuherberg, Germany
- 2Forschergruppe Diabetes e.V., Neuherberg, Germany
- 3Department of Clinical Sciences, Lund University, Skane University Hospital, Malmö, Sweden
- 4Pediatrics Epidemiology Center, University of South Florida, Tampa, FL
- 5FIRS Laboratories, RSR Ltd., Cardiff, U.K.
- 6Center for Regenerative Therapies, Dresden University of Technology, Dresden, Germany
- Corresponding author: Peter Achenbach, .
OBJECTIVE Patients with latent autoimmune diabetes in adults (LADA) express autoantibodies against the 65-kDa isoform of GAD antibody (GADA). Intervention with recombinant human GAD65 formulated with aluminium hydroxide (GAD-alum) given twice subcutaneously to LADA patients at intervals of 4 weeks was safe and did not compromise β-cell function in a Phase II clinical trial. GADA affinity has been shown to predict progression to type 1 diabetes. Here, we asked whether GADA affinity was affected by the GAD65 antigen-specific vaccination and/or associated with β-cell function in participants of this trial.
RESEARCH DESIGN AND METHODS GADA affinity was measured in sera of 46 LADA patients obtained prior to the 1st week and 20 weeks after the second injection with GAD-alum or placebo using competitive binding experiments with [125I]-labeled and unlabeled human GAD65.
RESULTS At baseline, GADA affinities ranged from 1.9 × 107 to 5.0 × 1012 L/mol (median 2.8 × 1010 L/mol) and were correlated with GADA titers (r = 0.47; P = 0.0009), fasting (r = −0.37; P = 0.01) and stimulated (r = −0.40; P = 0.006) C-peptide concentrations, and HbA1c (r = 0.39; P = 0.007). No significant changes in affinity were observed from baseline to week 24. Patients with GADA affinities in the lower first quartile (<4 × 109 L/mol) had better preserved fasting C-peptide concentrations at baseline than those with higher affinities (mean 1.02 vs. 0.66 nmol/L; P = 0.004) and retained higher concentrations over 30 months of follow-up (mean 1.26 vs. 0.62 nmol/L; P = 0.01).
CONCLUSIONS Intervention with GAD-alum in LADA patients had no effect on GADA affinity. Our data suggest that patients with low GADA affinity have a prolonged preservation of residual β-cell function.
- Received July 22, 2013.
- Accepted January 30, 2014.
- © 2014 by the American Diabetes Association.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.